OBJECTIVES: The aim of this study was to compare the survival benefits associated with gemcitabine chemotherapy and 5-fluorouracil (5-FU)-based concurrent chemoradiotherapy (CCRT) in locally advanced unresectable pancreatic cancer. METHODS: One hundred and thirty-eight locally advanced unresectable pancreatic cancer patients were retrospectively enrolled from January 1995 to January 2005. All cases were histologically proven, and patients received gemcitabine chemotherapy, 5-FU-based CCRT, or supportive care at Seoul National University Hospital. RESULTS: Median overall survival was 8.2 months. Twenty-six patients received gemcitabine chemotherapy, 56 patients 5-FU-based CCRT, and 56 patients supportive care. Weight loss and treatment modality were identified as independent prognostic factors by multivariate analysis. Patients in the 5-FU-based CCRT (overall survival, 10.4 months) and gemcitabine chemotherapy (11.3 months) groups showed survival benefit over those received supportive care (6.1 months, P < 0.0001). No grades 3 to 4 toxic adverse effects occurred in either treatment group and no statistical significant survival difference was found between gemcitabine chemotherapy and 5-FU-based CCRT (P = 0.5). CONCLUSIONS: Patients with locally advanced pancreatic cancer who received gemcitabine chemotherapy or 5-FU-based CCRT showed better survival than those who received supportive care only. Gemcitabine chemotherapy and 5-FU-based CCRT showed similar survival advantages.
OBJECTIVES: The aim of this study was to compare the survival benefits associated with gemcitabine chemotherapy and 5-fluorouracil (5-FU)-based concurrent chemoradiotherapy (CCRT) in locally advanced unresectable pancreatic cancer. METHODS: One hundred and thirty-eight locally advanced unresectable pancreatic cancerpatients were retrospectively enrolled from January 1995 to January 2005. All cases were histologically proven, and patients received gemcitabine chemotherapy, 5-FU-based CCRT, or supportive care at Seoul National University Hospital. RESULTS: Median overall survival was 8.2 months. Twenty-six patients received gemcitabine chemotherapy, 56 patients5-FU-based CCRT, and 56 patients supportive care. Weight loss and treatment modality were identified as independent prognostic factors by multivariate analysis. Patients in the 5-FU-based CCRT (overall survival, 10.4 months) and gemcitabine chemotherapy (11.3 months) groups showed survival benefit over those received supportive care (6.1 months, P < 0.0001). No grades 3 to 4 toxic adverse effects occurred in either treatment group and no statistical significant survival difference was found between gemcitabine chemotherapy and 5-FU-based CCRT (P = 0.5). CONCLUSIONS:Patients with locally advanced pancreatic cancer who received gemcitabine chemotherapy or 5-FU-based CCRT showed better survival than those who received supportive care only. Gemcitabine chemotherapy and 5-FU-based CCRT showed similar survival advantages.
Authors: Bilal Bin Hafeez; Ala Mustafa; Joseph W Fischer; Ashok Singh; Weixiong Zhong; Mohammed Ozair Shekhani; Louise Meske; Thomas Havighurst; KyungMann Kim; Ajit Kumar Verma Journal: Antioxid Redox Signal Date: 2014-02-06 Impact factor: 8.401
Authors: Timothy K Williams; Christina L Costantino; Nikolai A Bildzukewicz; Nathan G Richards; David W Rittenhouse; Lisa Einstein; Joseph A Cozzitorto; Judith C Keen; Abhijit Dasgupta; Myriam Gorospe; Gregory E Gonye; Charles J Yeo; Agnieszka K Witkiewicz; Jonathan R Brody Journal: PLoS One Date: 2010-11-29 Impact factor: 3.240
Authors: Jae Young Lee; Byung Ihn Choi; Ji Kon Ryu; Yong-Tae Kim; Joo Ha Hwang; Se Hyung Kim; Joon Koo Han Journal: Korean J Radiol Date: 2011-03-03 Impact factor: 3.500